Related Experiment Video

Updated: May 31, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prolonged remission of fulminant castrate-resistant prostate cancer: a case report

Mehmet Asim Bilen1, Rosale General, Shi-Ming Tu

  • 1Department of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

Clinical Genitourinary Cancer
|July 7, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Related Experiment Videos

Last Updated: May 31, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis.

Clinical genitourinary cancer·2026

Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.

Prostate cancer and prostatic diseases·2026

A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study.

European journal of cancer (Oxford, England : 1990)·2026

Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177-PSMA-617.

The oncologist·2026

Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance.

bioRxiv : the preprint server for biology·2026

Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases.

bioRxiv : the preprint server for biology·2026

EVOLUTE: Enfortumab Vedotin in OLder patients with locally advanced/metastatic UroThElial carcinoma.

Clinical genitourinary cancer·2026

Impact of Age on Outcomes in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT).

Clinical genitourinary cancer·2026

Accuracy of Intraoperative Frozen Section Analysis of Sentinel Node Biopsies in Penile Cancer.

Clinical genitourinary cancer·2026

The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy.

Clinical genitourinary cancer·2026

Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis).

Clinical genitourinary cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us